Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Boosters protect against SARS-CoV-2 infections in young adults during an Omicron-predominant period

View ORCID ProfileJiayue Wan, Casey L. Cazer, Marin E. Clarkberg, Shane G. Henderson, Scarlett E. Lee, Genevive Meredith, Marwan Osman, David B. Shmoys, Peter I. Frazier
doi: https://doi.org/10.1101/2022.03.08.22272056
Jiayue Wan
1School of Operations Research and Information Engineering, Cornell University College of Engineering, Ithaca, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jiayue Wan
Casey L. Cazer
2Department of Public and Ecosystem Health, Cornell University College of Veterinary Medicine, Ithaca, NY, USA
3Department of Population Medicine and Diagnostic Sciences, Cornell University College of Veterinary Medicine, Ithaca, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marin E. Clarkberg
4Institutional Research and Planning, Cornell University, Ithaca, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shane G. Henderson
1School of Operations Research and Information Engineering, Cornell University College of Engineering, Ithaca, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scarlett E. Lee
5Department of Microbiology and Immunology, Cornell University College of Veterinary Medicine, Ithaca, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Genevive Meredith
2Department of Public and Ecosystem Health, Cornell University College of Veterinary Medicine, Ithaca, NY, USA
6Master of Public Health Program, Cornell University, Ithaca, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: grm79@cornell.edu
Marwan Osman
2Department of Public and Ecosystem Health, Cornell University College of Veterinary Medicine, Ithaca, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David B. Shmoys
1School of Operations Research and Information Engineering, Cornell University College of Engineering, Ithaca, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter I. Frazier
1School of Operations Research and Information Engineering, Cornell University College of Engineering, Ithaca, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background While booster vaccinations clearly reduce the risk of severe COVID-19 and death, the impact of boosters on SARS-CoV-2 infection has not been fully characterized: doing so requires understanding their impact on asymptomatic and mildly symptomatic infections that often go unreported but nevertheless play an important role in spreading SARS-CoV-2. We sought to estimate the impact of COVID-19 booster doses on SARS-CoV-2 infection in a vaccinated and actively surveilled population of young adults during an Omicron-predominant period.

Methods and Findings We implemented a cohort study of young adults in a college environment (Cornell University’s Ithaca campus) from December 5, 2021 through December 31, 2021 when Omicron was deemed the predominant SARS-CoV-2 variant on campus. Participants included 15,102 university students fully vaccinated with an FDA-authorized or approved vaccination (BNT162b2, mRNA-1273, or Ad26.COV2.S) who were enrolled in mandatory at-least-weekly surveillance PCR testing, and having no positive SARS-CoV-2 PCR test within 90 days before the start of the study period. Multivariable logistic regression considering those with full vaccination (a 2-dose series of BNT162b2 or mRNA-1273, or 1 dose of Ad26.COV2.S) with a booster dose versus those without a booster dose. 1,870 SARS-CoV-2 infections were identified in the study population. Controlling for gender, student group membership, full vaccination date and initial vaccine type, our analysis estimates that receiving a booster dose reduces the odds of having a PCR-detected SARS-CoV-2 infection relative to full vaccination by 52% (95% confidence interval [37%, 64%]). This result is robust to the choice of the delay over which a booster dose becomes effective (varied from 1 day to 14 days).

Conclusions Boosters are effective, relative to full vaccination, in reducing the odds of SARS-CoV-2 infections in a college student population during a period when Omicron was predominant. Therefore, booster vaccinations for this age group can play an important role in reducing community and institutional transmission.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

JW and MO were supported by the Cornell University Office of the Provost. PF was supported by AFOSR FA9550-19-1-0283. SH was supported by NSF CMMI-2035086. DS was supported by NSF DCCF-1740822 and NSF DCCF-1522054. CC was supported by The David and Lucile Packard Foundation 2021-72608.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This work was completed as a part of Cornell University's institutional COVID-19 Modeling Team's contribution to institutional planning and preparedness, and was thus designated by IRB of Cornell University as exempt from IRB review.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data presented in the study are available upon reasonable request to the authors. One may contact Cornell University to request the de-identified, source data necessary to replicate the findings in this study.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted March 09, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Boosters protect against SARS-CoV-2 infections in young adults during an Omicron-predominant period
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Boosters protect against SARS-CoV-2 infections in young adults during an Omicron-predominant period
Jiayue Wan, Casey L. Cazer, Marin E. Clarkberg, Shane G. Henderson, Scarlett E. Lee, Genevive Meredith, Marwan Osman, David B. Shmoys, Peter I. Frazier
medRxiv 2022.03.08.22272056; doi: https://doi.org/10.1101/2022.03.08.22272056
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Boosters protect against SARS-CoV-2 infections in young adults during an Omicron-predominant period
Jiayue Wan, Casey L. Cazer, Marin E. Clarkberg, Shane G. Henderson, Scarlett E. Lee, Genevive Meredith, Marwan Osman, David B. Shmoys, Peter I. Frazier
medRxiv 2022.03.08.22272056; doi: https://doi.org/10.1101/2022.03.08.22272056

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (174)
  • Allergy and Immunology (421)
  • Anesthesia (97)
  • Cardiovascular Medicine (901)
  • Dentistry and Oral Medicine (170)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (407)
  • Epidemiology (8790)
  • Forensic Medicine (4)
  • Gastroenterology (405)
  • Genetic and Genomic Medicine (1864)
  • Geriatric Medicine (179)
  • Health Economics (388)
  • Health Informatics (1292)
  • Health Policy (644)
  • Health Systems and Quality Improvement (492)
  • Hematology (207)
  • HIV/AIDS (395)
  • Infectious Diseases (except HIV/AIDS) (10567)
  • Intensive Care and Critical Care Medicine (564)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1756)
  • Nursing (103)
  • Nutrition (266)
  • Obstetrics and Gynecology (343)
  • Occupational and Environmental Health (461)
  • Oncology (965)
  • Ophthalmology (283)
  • Orthopedics (107)
  • Otolaryngology (177)
  • Pain Medicine (118)
  • Palliative Medicine (43)
  • Pathology (264)
  • Pediatrics (557)
  • Pharmacology and Therapeutics (266)
  • Primary Care Research (219)
  • Psychiatry and Clinical Psychology (1845)
  • Public and Global Health (3986)
  • Radiology and Imaging (655)
  • Rehabilitation Medicine and Physical Therapy (344)
  • Respiratory Medicine (535)
  • Rheumatology (215)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (166)
  • Surgery (197)
  • Toxicology (37)
  • Transplantation (106)
  • Urology (80)